Table 2.
Comparison of presenting features and treatments between survivor participants with or without ovarian transposition
| Ovarian
transposition (N=49) |
Non-ovarian
transposition (N=41) |
P Value | |
|---|---|---|---|
| Age at diagnosis, Median (range) | 15 (4-19) | 16 (6-22) | 0.0417 |
| Age at Questionnaire, Median (range) | 38 (25-51) | 39 (26-60) | 0.9353 |
| Age at primary ovarian insufficiency, Median (range) | 22.7 (15.3-38.2) | 17.9 (15.5-35.0) | 0.2629 |
| Race | 0.9626 | ||
| White | 42 (85.7) | 35 (85.4) | |
| Non-white | 7 (14.3) | 6 (14.6) | |
| Alkylating Agent Cyclophosphamide Equivalent Dose (N, %), mg/m2 | 0.0445 | ||
| 0 to <= 8000 | 19 (39.6) | 26 (66.7) | |
| 8000 to <= 12000 | 12 (25.0) | 6 (15.4) | |
| 12000 to <= 20000 | 13 (27.1) | 7 (18.0) | |
| > 20000 | 4 (8.3) | 0 (0.0) | |
| Median (range) | 10151.7 (1806.2-28980.0) | 7434.6 (1800.0-16486.8) | |
| Pelvic radiation dose (N, %), cGy | <.0001 | ||
| ≤ 1500 | 9 (18.4) | 23 (60.5) | |
| > 1500 | 40 (81.6) | 15 (39.5) | |
| Pregnancy | 0.1459 | ||
| Yes | 30 (61.2) | 31 (75.6) | |
| No | 19 (38.8) | 10 (24.4) | |
| Age at first pregnancy, Median (range) | 23.5 (17.0-38.0) | 22.0 (13.0-34.0) | 0.1693 |
| Live birth delivery* | 0.9663 | ||
| Yes | 27 (90.0) | 28 (90.3) | |
| No | 3 (10.0) | 3 (9.7) | |
| Age at first live birth delivery, Median (range) | 24.0 (17.0-36.0) | 22.5 (16.0-34.0) | 0.3272 |
*
Analysis for the live birth delivery was based on patients who have reported pregnancy (N=61, 30 in OT and 31 in non-OT group)